Abstract
Refractory T-lymphoblastic leukemia in adults has a poor prognosis in patients who relapse after allogeneic stem cell transplantation, and relatively few new agents have demonstrated activity. Clofarabine is a novel nucleoside analog that has been associated with significant clinical activity in relapsed pediatric B-ALL. We used low dose clofarabine and induced a remission in a patient who relapsed in the skin and marrow after allogeneic transplant and was refractory to nelarabine and report a near complete response, suggesting significant activity for low intermittent dose clofarabine in patients with relapsed T-cell leukemias.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 169-172 |
| Number of pages | 4 |
| Journal | Yale Journal of Biology and Medicine |
| Volume | 79 |
| Issue number | 3-4 |
| State | Published - Dec 2006 |
ASJC Scopus subject areas
- General Biochemistry, Genetics and Molecular Biology